ACR Meeting Abstracts

ACR Meeting Abstracts

  • Home
  • Meetings Archive
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP PRSYM
    • 2016-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • Meeting Resource Center

Abstracts tagged "Cytotoxic Cells"

  • Abstract Number: 0967 • ACR Convergence 2021

    Antigen-specific and Bystander Autoreactive T Cell Control in Peripheral Blood of ACPA+ Rheumatoid Arthritis Patients Administered Antigen-specific Tolerising Immunotherapy

    Pascale Wehr1, Ranjeny Thomas2, Nishta Ramnoruth3, Swati Patel3, Jamie Rossjohn4 and Hugh Reid4, 1University of Queensland Diamantina Institute, Brisbane, Australia, 2University of Queensland, Diamantina Institute, Brisbane, Australia, 3University Of Queensland, Brisbane, Australia, 4Monash University, Melbourne, Australia

    Background/Purpose: The control of autoreactive T cells in an antigen-specific manner in autoimmune diseases is a major clinical research goal. Various regulatory immune signatures have…
  • Abstract Number: 0993 • ACR Convergence 2021

    The Mechanistic Basis of anti-CD6 as a Novel Form for the Treatment of Autoimmune Diseases and Cancer

    Mikel Gurrea-Rubio1, Jeffrey Ruth1, Qi Wu1, Eliza Pei-Suen Tsou1, Phillip Campbell1, Peggy Randon1, M.Asif Amin1, Nora Singer2, Feng Lin3 and David Fox1, 1University of Michigan, Ann Arbor, MI, 2The MetroHealth System, Cleveland, OH, 3Cleveland Clinic, Cleveland, OH

    Background/Purpose: The use of Immune Checkpoint Inhibitors (ICIs) is limited by the induction of immune-related adverse events. CD6 is expressed by most T lymphocytes and…
  • Abstract Number: 1772 • ACR Convergence 2021

    Autologous EBV-specific Cytotoxic T Cells in Systemic Lupus Erythematosus: An Innovative Phase I/IIa Clinical Trial

    Antoine Enfrein1, Beatrice Clemenceau2, Soraya Saiagh3, Céline Bressollette4, Zahir Amoura5, Henri Vie2 and Mohamed Hamidou1, 1Médecine interne, CHU de Nantes, Nantes, France, 2Inserm U1232, Université de Nantes, Nantes, France, 3Unité de Thérapie Cellulaire et Génique, CHU de Nantes, Nantes, France, 4Laboratoire de Virologie, CHU de Nantes, Nantes, France, 5Médecine interne, Hôpital Pitié Salpêtrière, AP-HP, Paris, France

    Background/Purpose: Epstein-Barr Virus (EBV) has been suggested as a potential environmental factor in systemic lupus erythematosus (SLE) onset and disease activity. Here, we report the…
  • Abstract Number: 0449 • ACR Convergence 2020

    Cytotoxic T Cells with a Chronic Antigen Exposure Phenotype Drive Immune Checkpoint Inhibitor Sicca

    Blake Warner1, Billel Gasmi2, David Kleiner3, Paola Perez Riveros4, Daniel Barber5, Shunsuke Sakai5 and Alan Baer6, 1National Institute of Dental and Craniofacial Research, Bethesda, 2National Cancer Institute, Bethesda, MD, 3National Cancer Institute, Bethesda, 4National Institute of Dental and Craniofacial Research, Bethesda, MD, 5National Institute of Allergy and Infectious Disease, Bethesda, MD, 6Johns Hopkins University School of Medicine, Baltimore, MD

    Background/Purpose: Immune checkpoint inhibitors (ICI) have advanced the field of cancer therapeutics. By blocking the negative co-stimulation of T cells, ICI augment the anti-tumor immune…
  • Abstract Number: 0473 • ACR Convergence 2020

    Characterization of DOCK8 as a Novel Gene Associated with Cytokine Storm Syndrome

    Mingce Zhang1, Remy Cron2, Devin Absher3, Prescott Atkinson1, Winn Chatham1 and Randy Cron1, 1University of Alabama at Birmingham, Birmingham, AL, 2University of Alabama at Birmingham, Birmingham, 3HudsonAlpha Institute for Biotechnology, Huntsville, AL

    Background/Purpose: Cytokine storm syndrome (CSS), also known as macrophage activation syndrome (MAS) or secondary hemophagocytic lymphohistiocytosis (HLH), is a life threatening condition that commonly presents…
  • Abstract Number: 0846 • ACR Convergence 2020

    MHC Class I Epitopes Derived from Autoantibody Variable Regions, Conjugated to Synthetic Oligodeoxynuleotides, Induce Cytotoxic T Cells That Deplete Autoreactive B Cells and Ameliorate Murine Lupus

    Ram Singh1, 1UCLA David Geffen School of Medicine, Los Angeles, CA

    Background/Purpose: B cell depletion or modulation is emerging as a major treatment modality for autoimmune diseases. However, the current treatments to accomplish this non-specifically target…
  • Abstract Number: 1443 • ACR Convergence 2020

    High-dimensional Analyses of Checkpoint-inhibitor Related Arthritis Synovial Fluid Cells Reveal a Unique, Proliferating CD38hi Cytotoxic CD8 T Cell Population Induced by Type I IFN

    Runci Wang1, Karmela Kim Chan2, Amy Cunningham-Bussel1, Gregory Vitone3, Aidan Tirpack2, Caroline Benson2, Gregory Keras4, Anna Helena Jonsson5, Michael Brenner5, Laura Donlin6, Anne Bass7 and Deepak Rao1, 1Brigham and Women's Hospital, Boston, MA, 2Hospital For Special Surgery, New York, NY, 3Hospital for Special Surgery, New York, 4Brigham and Women’s Hospital, Division of Rheumatology, Inflammation, and Immunity, Boston, MA, 5Brigham and Women's Hospital and Harvard Medical School, Boston, MA, 6Hospital for Special Surgery, Weill Cornell Medicine, New York, 7Hospital for Special Surgery/Weill Cornell Medicine, New York, NY

    Background/Purpose: Checkpoint inhibitors (CI) used to treat cancer frequently trigger immune-related adverse events, including inflammatory arthritis. CI-related arthritis (CIrA) occurs in ~5% of treated patients,…
  • Abstract Number: 1575 • ACR Convergence 2020

    CD6 Is a Target for Cancer Immunotherapy

    Jeffrey Ruth1, Mikel Gurrea Rubio2, Kalana Athukorala3, Stephanie Rasmussen1, Weber Daniel1, Peggy Randon1, M Asif Amin1, Phillip Campbell1, Pei-suen Tsou1, Yang Mao-Draayer1, Qi Wu4, Matthew Lind1, Rosemary Gedert1, Thomas Lanigan1, Venkateshwar Keshamouni1, Nora Singer5, Feng Lin6 and David Fox7, 1University of Michigan, Ann Arbor, MI, 2Division of Rheumatology, University of Michigan, Canton, MI, 3University of Michigan, Ann Arbor, MN, 4University of Michigan, Ann Arbor, 5The MetroHealth System, Case Western Reserve University School of Medicine, Cleveland, OH, 6Cleveland Clinic Foundation, Cleveland, OH, 7Division of Rheumatology, University of Michigan, Ann Arbor, MI

    Background/Purpose: Limitations of checkpoint inhibitor immunotherapy include induction of autoimmune syndromes and resistance of many cancers. Definition of additional molecular targets is required. CD6, expressed…
  • Abstract Number: 2047 • ACR Convergence 2020

    Synovial CD8 T Cells in Rheumatoid Arthritis Exhibit High Antigen-independent Cytokine Production and Low Cytotoxic Potential

    Anna Helena Jonsson1, Fan Zhang2, Emma Gomez-Rivas3, Karishma Rupani4, Gerald Watts5, Kevin Wei1, Runci Wang4, Deepak Rao4, Accelerating Medicines Partnership (AMP) - RA/SLE6, Soumya Raychaudhuri2 and Michael Brenner1, 1Brigham and Women's Hospital and Harvard Medical School, Boston, MA, 2Brigham and Women’s Hospital and Harvard Medical School, Boston, MA, 3Division of Rheumatology, Brigham and Women's Hospital, Boston, MA, 4Brigham and Women's Hospital, Boston, MA, 5Brigam and Women's Hospital, Boston, 6., Boston

    Background/Purpose: T cell-derived pro-inflammatory cytokines are major drivers of RA pathogenesis, and these cytokines have traditionally been attributed to CD4 T cells.  However, single-cell RNA-sequencing…
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

ACR Pediatric Rheumatology Symposium 2020

© COPYRIGHT 2022 AMERICAN COLLEGE OF RHEUMATOLOGY

Wiley

  • Home
  • Meetings Archive
  • Advanced Search
  • Meeting Resource Center
  • Online Journal
  • Privacy Policy
  • Permissions Policies